Overview
Transgene is a clinical-stage biotechnology company developing virus-based immunotherapies, primarily for cancer treatment. Key offerings include TG4050, an individualized neoantigen therapeutic vaccine using MVA viral vector technology combined with AI-driven neoantigen prediction. These therapies target solid tumors like head and neck cancer to stimulate patient-specific immune responses and prevent relapse.
Frequently asked questions
- What are Transgene's main therapeutic capabilities?
- Transgene specializes in virus-based immunotherapies using myvac® MVA viral vector platform for individualized neoantigen vaccines like TG4050 targeting cancer neoantigens.
- What is the development stage of TG4050?
- TG4050 is in clinical evaluation for resected HPV-negative head and neck cancer, assessing relapse prevention post-surgery and adjuvant therapy in Phase 2 trials.
- What technologies power Transgene's products?
- Products leverage bioengineering, viral vectorization, AI/ML for neoantigen selection via partnerships like NEC, and digital transformation for oncology applications.